Arcutis Biotherapeutics ( (ARQT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arcutis Biotherapeutics shares climbed after Wall Street analysts reiterated their bullish stance on the company. Guggenheim reaffirmed its Buy rating, highlighting a positive outlook for the business, while BTIG also restated its Buy rating, reinforcing strong investor confidence. Following these calls, Guggenheim set a price target of $34 and BTIG set theirs at $31. The stock last closed at $28.01, and the average analyst target of $30.25 still points to further upside, supported by an overall Strong Buy consensus.
More about Arcutis Biotherapeutics
YTD Price Performance: 92.38%
Average Trading Volume: 2,435,930
Technical Sentiment Signal: Buy
Current Market Cap: $3.43B
For further insights into ARQT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.